Close
Nordic 9Nordic 9

Takeda Pharmaceutical Company Limited (investor - Corporate Investor)

Japan takeda.com
See something wrong or missing? Let us know
Offices:Osaka

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company in Japan and invests also via Takeda Ventures.

Average round investment:23.41M USD
Average number per year:2.0
Distribution: 2025 (1)2022 (2)2021 (3)2020 (2)
Portfolio companies: Spain Integra TxNetherlands EnzyreNorway Zelluna Immunotherapy As See the entire list
Mostly invests in: Spain Spain (2) Biotech (7)
See the entire list

Showing 3 of 8 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Takeda Pharmaceutical Company Limited

Name Criteria
Malta Elevat3 Capital
92%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Manufacturing, Software Services
  • Similar business models: B2B, SAAS
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
United States Intel Capital
92%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Software Services
  • Similar business models: B2B, SAAS
  • Common investees countries: Spain, France, United Kingdom, Norway
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
Netherlands Thomas Plantenga
92%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Software Services
  • Similar business models: B2B, SAAS
  • Common investees countries: France, Netherlands
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
France IDIA Capital Investissement
92%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing, Software Services
  • Similar business models: B2B, SAAS
  • Common investees countries: France
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
France Benjamin Netter
92%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Software Services
  • Similar business models: B2B, SAAS
  • Common investees countries: France, United Kingdom
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
France Éric Carreel
92%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Software Services
  • Similar business models: B2B, SAAS
  • Common investees countries: France
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
United Kingdom HPE Growth
92%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Software Services
  • Similar business models: B2B, SAAS
  • Common investees countries: United Kingdom, Netherlands
  • Average number of deals per year: 2.2
  • Active last 12 months: Yes
United States Cargill
92%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing, Software Services
  • Similar business models: B2B, SAAS
  • Common investees countries: Spain, France, Netherlands
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
South Korea Korea Investment Partners
92%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing, Software Services
  • Similar business models: B2B, SAAS
  • Common investees countries: France, United Kingdom
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
United States New Science Ventures
92%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing, Software Services
  • Similar business models: B2B, SAAS
  • Common investees countries: United Kingdom, Netherlands
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
Top